PharmaBoardroom

China: Yangtze River Pharmaceutical Group (YRPG) in Profile

One of the largest domestic pharma companies in China (ranking number one from 2014 to 2019), Yangtze River Pharmaceutical Group (YRPG) is so-named…

New Drug Approvals in China 2020

The Chinese NMPA’s drug approval list for 2020 includes a surge in approvals for locally developed drugs. A total of 46 new drugs were approved in…

STADA’s Bold Bets on M&A

After a year of growth and acquisitions, 125-year-old German generics manufacturer STADA is showing a willingness to make bold bets on areas including…

New Drug Approvals in China in 2020

Writing in the February edition of DIA’s Global Forum magazine, Xu Wang of Novo Nordisk Pharma China and Xiaoxi Wang from the Shanghai Center for…

Alvotech’s Four Traits for Biosimilars Success

Alvotech – the biosimilars arm of Icelandic-headquartered generics player Alvogen – is positioning itself for future growth via a very different…

Japan’s Taiho Pharmaceutical: An Oral Chemotherapy Pioneer

Japanese pharma companies are already far lower-profile than their occidental counterparts but an even lesser-known player may be Taiho…

Novartis Oncology US: Leaning into Change

With a series of reorganization initiatives, new leaders at the helm and exciting acquisitions, Novartis Oncology has undergone a significant business…

Eisai Targeting Global Leadership in Neurology & Oncology…

Founded by Toyoji Naito in December 1941, in just under 80 years, Eisai has become a leading global biopharma player, with pharmaceutical revenues of…